Clinical trials: Breast Cancer Patients
Breast Cancer
Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
This is a prospective open-label one-arm phase III trial designed to evaluate the safety and efficacy of letrozole 2.5 mg administered orally daily for 24 months as adjuvant therapy in postmenopausal patients with primary breast…
- Trial name
- NCT00332852
- Testing
- Letrozole
- Where
- 53 sites in Germany
- Volunteers
- 655 people
- Sponsor
- Novartis Pharmaceuticals
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor…
- Trial name
- NCT01889238
- Testing
- Enzalutamide
- Where
- 132 sites in United States, Belgium and 5 more
- Volunteers
- 118 people
- Sponsor
- Pfizer
DCIS
The AUS-PREDICT Registry for DCIS Patients With DCISionRT Testing
This is a prospective cohort study for patients diagnosed with ductal carcinoma in situ (DCIS) of the breast. The primary objective of the study is to create a de-identified database of patients, test results, treatment decisions…
- Trial name
- AUS-PREDICT (NCT04916808)
- Testing
- DCISionRT Test
- Where
- 2 sites in Australia
- Volunteers
- 1,500 people
- Sponsor
- PreludeDx
Breast Cancer, Triple Negative Breast Cancer
Prospective Evaluation of AI R&D Tool for Patient Stratification - MoA Evaluation in Triple Negative Breast Cancer (PEAR-MET)
Pear Bio has developed an organ-on-a-chip device together with a computer vision pipeline through which the response of an individual patient's tumor to different systemic therapy regimens can be tested simultaneously ex vivo.
- Trial name
- PEAR-MET (NCT06182306)
- Testing
- Biopsy
- Where
- 3 sites in United Kingdom
- Volunteers
- 30 people
- Sponsor
- Ourotech, Inc.
Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma
A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors
This study will evaluate the safety, tolerability, and preliminary antitumor activity of CAN04 both as a monotherapy and in combination with standard of care treatment in subjects with solid cancer tumors.
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma, Triple Negative Breast Cancer, Colorectal Cancer
- Trial name
- CANFOUR (NCT03267316)
- Testing
- CAN04, Cisplatin, Gemcitabine
- Where
- 25 sites in Austria, Belgium and 9 more
- Volunteers
- 167 people
- Sponsor
- Cantargia AB
Solid Tumor
A Phase 1a/1b Study of ACTM-838 in Patients With Advanced Solid Tumors
This is a first in human (FIH) 2-part study using ACTM-838 in patients with advanced solid tumors resistant to standard of care treatment. Part 1a will evaluate dose escalation and Part 1b will evaluate dose expansion.
- Trial name
- NCT06336148
- Testing
- ACTM-838
- Where
- 5 sites in United States, Australia
- Volunteers
- 10 people
- Sponsor
- Actym Therapeutics, Inc.
Breast Cancer
Safety and Rheumatologic Tolerability of Letrozole in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
The purpose of this study is to assess rheumatologic tolerability of letrozole in postmenopausal patients with hormone receptor positive breast cancer having discontinued anastrozole adjuvant treatment due to musculoskeletal…
- Trial name
- NCT00329940
- Testing
- Letrozole
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Novartis Pharmaceuticals
Glioblastoma, Melanoma Stage IV
A Phase 1-2 Study of ST101 in Patients With Advanced Solid Tumors
This is an open-label, two-part, phase 1-2 dose-finding study designed to determine the safety, tolerability, PK, PD, and proof-of-concept efficacy of ST101 administered IV in patients with advanced solid tumors.
- Conditions
- Glioblastoma, Melanoma Stage IV, Breast Cancer, Prostate Cancer
- Trial name
- NCT04478279
- Testing
- ST101, Temozolomide, Radiation
- Where
- 11 sites in United States, United Kingdom
- Volunteers
- 125 people
- Sponsor
- Sapience Therapeutics
Advanced Breast Cancer
Clinical Study of Decitabine and Paclitaxel Combination Therapy
Phase Ib clinical study of Decitabine and Paclitaxel combination therapy
- Trial name
- NCT03282825
- Testing
- Decitabine, Paclitaxel
- Where
- South Korea
- Volunteers
- 18 people
- Sponsor
- Dong Wha Pharmaceutical Co. Ltd.
Melanoma, Non-small Cell Lung Cancer
A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies
This is a study to determine the maximum tolerated dose (MTD) for CDX-1140 (CD40 antibody), either alone or in combination with CDX-301 (FLT3L), pembrolizumab, or chemotherapy and to further evaluate its tolerability and efficacy…
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer
- Trial name
- NCT03329950
- Testing
- CDX-1140, CDX-301, pembrolizumab
- Where
- 11 sites in United States
- Volunteers
- 132 people
- Sponsor
- Celldex Therapeutics
Inoperable or Recurrent Breast Cancer
Post-marketing Surveillance for the Clinical Safety and Effectiveness of Eribulin Mesylate in Patients With Inoperable or Recurrent Breast Cancer (Study HAL01S)
To investigate of the clinical safety and effectiveness of eribulin mesylate in patients with inoperable or recurrent breast cancer
- Trial name
- NCT01463891
- Testing
- Eribulin Mesylate
- Where
- 223 sites in Japan
- Volunteers
- 963 people
- Sponsor
- Eisai Co., Ltd.
Hormon Receptor Positive Breast Cancer
Epidemiology Study in Postmenopausal Women With Estrogen Receptor Positive Breast Cancer
This observational study in estrogen receptor positive early breast cancer patients is aimed to evaluate the patients' compliance to aromatase inhibitor (AI) therapy and to collect country-specific data in estrogen receptor…
- Trial name
- NCT01208779
- Where
- 2 sites in Serbia
- Volunteers
- 90 people
- Sponsor
- AstraZeneca
HR Positive/HER-2 Negative Breast Cancer
A Phase Ib/Ⅱ Study of NTQ1062 in Combination With Fulvestrant in Patients With Advanced HR Positive /HER-2 Negative Breast Cancer
This is an open-label, single-arm phase 1b study to evaluate the safety, tolerability, pharmacokinetics, and preliminary anti-tumor efficacy of NTQ1062 in combination with Fulvestrant in patients with locally advanced or…
- Trial name
- NCT06172322
- Testing
- NTQ1062 with Fulvestrant
- Where
- China
- Volunteers
- 42 people
- Sponsor
- Nanjing Chia-tai Tianqing Pharmaceutical
Advanced Breast Cancer, Advanced Malignant Solid Tumor
A Study of MHB036C Combined With MHB039A in Patients With Advanced Breast Cancer or Other Advanced Malignant Solid Tumors
This is an open-label, multicenter Phase II study of MHB036C combined with MHB039A in patients with advanced Breast Cancer or other advanced malignant solid tumors.
- Trial name
- NCT07130383
- Testing
- MHB036C for Injection, MHB039A for Injection
- Where
- China
- Volunteers
- 210 people
- Sponsor
- Minghui Pharmaceutical (Hangzhou) Ltd
Breast Neoplasms
Study Of CP-751,871 In Combination With Exemestane In Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer
To test the efficacy of CP-751,871 combined with exemestane in the treatment of postmenopausal patients with hormone positive advanced breast cancer
- Trial name
- NCT00372996
- Testing
- CP-751,871, exemestane, Fulvestrant
- Where
- 62 sites in United States, Argentina and 7 more
- Volunteers
- 219 people
- Sponsor
- Pfizer
Carcinoma, Non-Small-Cell Lung, Triple Negative Breast Cancer
A Study of Dato-DXd in Chinese Patients With Advanced Non-Small Cell Lung Cancer, Triple-negative Breast Cancer and Other Solid Tumors (TROPION-PanTumor02)
Researchers are looking for a better way to treat advanced Triple-Negative Breast Cancer (TNBC) and Non-Small-Cell Lung Cancer (NSCLC). "Advanced" usually means that the cancer keeps growing even with treatment.
- Trial name
- NCT05460273
- Testing
- Datopotamab Deruxtecan (Dato-DXd)
- Where
- 21 sites in China
- Volunteers
- 119 people
- Sponsor
- AstraZeneca
Head and Neck Cancer, Cervical Cancer
A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies
This is a multicenter, open-label, phase Ib/IIa study. The first part of the study will evaluate the safety, tolerability and preliminary efficacy of ILB2109 and Toripalimab in patients with locally advanced or metastatic solid…
- Conditions
- Head and Neck Cancer, Cervical Cancer, Endometrial Cancer, Triple Negative Breast Cancer
- Trial name
- NCT05955105
- Testing
- ILB-2109, Toripalimab
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Innolake Biopharm
Breast Cancer
A Study of Herceptin (Trastuzumab) in Combination With a Taxane in Participants With HER2-Positive Breast Cancer Who Relapsed After (Neo)Adjuvant Herceptin Treatment
This single arm, open-label study will evaluate the efficacy and safety of Herceptin (trastuzumab) in combination with a taxane as first line therapy in participants with HER2-positive breast cancer who relapsed after neoadjuvant…
- Trial name
- NCT01301729
- Testing
- Docetaxel, Paclitaxel, Trastuzumab
- Where
- 17 sites in China
- Volunteers
- 32 people
- Sponsor
- Hoffmann-La Roche
Breast Cancer
A Study to Evaluate Erlotinib in Patients With Advanced or Metastatic Breast Cancer During or Following Chemotherapy
This is a Phase II, multicenter trial of single-agent treatment with OSI 774 in patients with histologically confirmed, incurable, locally advanced or metastatic breast cancer. Patients must have measurable disease.
- Trial name
- NCT00109265
- Testing
- Erlotinib HCl (OSI-774)
- Sponsor
- Genentech, Inc.
Breast Cancer
A Phase III Clinical Study of HRS-6209 Plus Letrozole as First-line Therapy in Patients With Advanced or Metastatic Breast Cancer
The purpose of this study is to investigate the efficacy and safety of HRS-6209 in combination with letrozole compared with dalpciclib or palbociclib in combination with aromatase inhibitor in patients with advanced or metastatic…
- Trial name
- NCT07894328
- Testing
- HRS-6209 + Letrozole, Dalpciclib/Palbociclib + Letrozole/Anastrozole
- Where
- China
- Volunteers
- 1,050 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.